 JNJ said Wednesday morning it had agreed to buy the biotech firm MNTA in an all-cash 6.5 billion deal, acquiring rights to Momentas experimental drug nipocalimab, which has potential uses in a number of autoimmune diseases. Shares of Momenta ticker: MNTA have jumped 69 on the news on Wednesday, while shares of Johnson Johnson JNJ were up 0.8. JNJ will broaden its leadership in immune-mediated diseases and drive further growth through expansion into autoantibody-driven disease with the acquisition of MNTA, wrote Cantor Fitzgerald analyst Louise Chen in a quick take published early Wednesday. 